Download
s12943-021-01339-1.pdf 1,60MB
WeightNameValue
1000 Titel
  • Clinical and immunological effects of mRNA vaccines in malignant diseases
1000 Autor/in
  1. Heine, Annkristin |
  2. Juranek, Stefan |
  3. Brossart, Peter |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-15
1000 Erschienen in
1000 Quellenangabe
  • 20(1):52
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12943-021-01339-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957288/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • In vitro-transcribed messenger RNA-based therapeutics represent a relatively novel and highly efficient class of drugs. Several recently published studies emphasize the potential efficacy of mRNA vaccines in treating different types of malignant and infectious diseases where conventional vaccine strategies and platforms fail to elicit protective immune responses. mRNA vaccines have lately raised high interest as potent vaccines against SARS-CoV2. Direct application of mRNA or its electroporation into dendritic cells was shown to induce polyclonal CD4+ and CD8+ mediated antigen-specific T cell responses as well as the production of protective antibodies with the ability to eliminate transformed or infected cells. More importantly, the vaccine composition may include two or more mRNAs coding for different proteins or long peptides. This enables the induction of polyclonal immune responses against a broad variety of epitopes within the encoded antigens that are presented on various MHC complexes, thus avoiding the restriction to a certain HLA molecule or possible immune escape due to antigen-loss. The development and design of mRNA therapies was recently boosted by several critical innovations including the development of technologies for the production and delivery of high quality and stable mRNA. Several technical obstacles such as stability, delivery and immunogenicity were addressed in the past and gradually solved in the recent years.This review will summarize the most recent technological developments and application of mRNA vaccines in clinical trials and discusses the results, challenges and future directions with a special focus on the induced innate and adaptive immune responses.
1000 Sacherschließung
lokal Gene Expression Regulation, Neoplastic [MeSH]
lokal Cancer
lokal Antigens, Neoplasm/genetics [MeSH]
lokal Immunity [MeSH]
lokal RNA, Messenger/immunology [MeSH]
lokal Immunotherapy [MeSH]
lokal RNA, Messenger/genetics [MeSH]
lokal B cells
lokal Tumor-associated antigen
lokal mRNA vaccine
lokal Neoplasms/pathology [MeSH]
lokal Lymphocytes, Tumor-Infiltrating/pathology [MeSH]
lokal Neoplasms/therapy [MeSH]
lokal Cancer Vaccines/administration
lokal RNA Stability [MeSH]
lokal T cells
lokal Immune response
lokal Cancer Vaccines/immunology [MeSH]
lokal Vaccines, Synthetic/immunology [MeSH]
lokal Humans [MeSH]
lokal Drug Delivery Systems [MeSH]
lokal Animals [MeSH]
lokal Lymphocytes, Tumor-Infiltrating/metabolism [MeSH]
lokal 2021 mRNA Special Issue
lokal Antigens, Neoplasm/immunology [MeSH]
lokal Lymphocytes, Tumor-Infiltrating/immunology [MeSH]
lokal Gene Transfer Techniques [MeSH]
lokal Vaccines, Synthetic/genetics [MeSH]
lokal Neoplasms/etiology [MeSH]
lokal COVID19
lokal Review
lokal Vaccines, Synthetic/administration
lokal Cancer Vaccines/genetics [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SGVpbmUsIEFubmtyaXN0aW4=|https://frl.publisso.de/adhoc/uri/SnVyYW5laywgU3RlZmFu|https://frl.publisso.de/adhoc/uri/QnJvc3NhcnQsIFBldGVy
1000 Hinweis
  • DeepGreen-ID: 94b2b9df1e2a4abc90a5f4e4acf46ce0 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6463333.rdf
1000 Erstellt am 2023-11-15T18:00:33.027+0100
1000 Erstellt von 322
1000 beschreibt frl:6463333
1000 Zuletzt bearbeitet 2023-11-30T21:28:06.095+0100
1000 Objekt bearb. Thu Nov 30 21:28:06 CET 2023
1000 Vgl. frl:6463333
1000 Oai Id
  1. oai:frl.publisso.de:frl:6463333 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source